SE

Shanghai East Hospital at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Shanghai East Hospital takes part in 3 sessions at ESMO 2026 in Madrid. Its sessions centre on new antibody drugs, including bispecific, trispecific and drug-conjugated antibodies, in advanced non-small cell lung cancer and other solid tumours. It presents a phase 3 comparison of sacituzumab tirumotecan plus pembrolizumab against chemotherapy plus pembrolizumab as first-line treatment for PD-L1-negative non-squamous disease.

Organization

ESMO 2026 Attendance

SE

Shanghai East Hospital

Shanghai, China

Cancer centre & hospital

Teaching hospital of Tongji University in Shanghai, China.

Abstract

Sat Oct 24
14:45–14:55

999O - Elfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) + pumitamig (PD-L1 x VEGF-A bsAb) in patients with advanced solid tumors: First results from a global phase 2 trial

Proffered paper: Developmental therapeutics

Abstract

Sun Oct 25
08:35–08:40

2616RO - A phase 2 study of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer (NSCLC)

Rapid oral 2: NSCLC, metastatic

Lung & thoracic cancers

Abstract

Sun Oct 25
10:53–11:03

LBA66 - Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: randomized phase 3 OptiTROP-Lung06 study

Proffered paper 1: NSCLC, metastatic

Lung & thoracic cancers

Instantly find 20 buyers from Shanghai East Hospital

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction